Skip to content

Clinical Trials

Below, please find a listing of VentiRx Pharmaceuticals’ active clinical trials and links to additional trial protocol information for these studies as posted on the National Instiutes of Health (NIH) clinical trials website (www.clinicaltrials.gov). For general information on clinical trials, terms related to clinical trials and other general health information, please visit the NIH website.

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

A Phase I trial to evaluate the safety and best dose of TLR8 agonist VTX-2337 when given together with cetuximab in patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck (SCCHN).

More information about this ongoing trial can be found at clinicaltrials.gov.

VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

A Phase I trial to evaluate the safety and dose best dose of VTX-2337 and liposomal doxorubicin hydrochloride in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer.

More information about this ongoing trial can be found at clinicaltrials.gov.

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

A Phase I/II trial to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma.

More information about this ongoing trial can be found at clinicaltrials.gov.

TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

A Phase I/II study to evaluate the local and systemic anti-tumor effects of intratumoral injection of VTX-2337 in combination n combination with low-dose local radiation at a single tumor site, in patients with recurrent b-cell lymphoma.

More information about this ongoing trial can be found at clinicaltrials.gov.

VTX-2337 is currently being investigated in clinical trials and has not received U.S. F.D.A. approval. VentiRx Pharmaceuticals does not claim that this technology or any of its product candidates are safe or will be effective in preventing, treating or curing any disease or condition.